Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ENTA
- CUSIP: N/A
- Web: www.enanta.com
Capitalization:- Market Cap: $815.35 million
- Outstanding Shares: 19,090,000
Average Prices:- 50 Day Moving Avg: $41.09
- 200 Day Moving Avg: $34.67
- 52 Week Range: $22.17 - $45.74
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -45.79
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $39.73 million
- Price / Sales: 20.90
- Book Value: $13.66 per share
- Price / Book: 3.18
Profitability:- EBIDTA: ($30,750,000.00)
- Net Margins: -51.85%
- Return on Equity: -7.74%
- Return on Assets: -7.39%
Debt:- Current Ratio: 18.53%
- Quick Ratio: 18.54%
Misc:- Average Volume: 207,289 shs.
- Beta: 0.64
- Short Ratio: 5.57
Frequently Asked Questions for Enanta Pharmaceuticals (NASDAQ:ENTA)
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.05. The firm earned $7.51 million during the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The business's revenue for the quarter was down 46.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.06) earnings per share. View Enanta Pharmaceuticals' Earnings History.
When will Enanta Pharmaceuticals make its next earnings announcement?
Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?
4 brokers have issued 1 year price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $36.00 to $40.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $38.00 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Momenta Pharmaceuticals (MNTA), Esperion Therapeutics (ESPR), Genus plc (GNS), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Spectrum Pharmaceuticals (SPPI) and CRISPR THERAPTC (CRSP).
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Bruce L.A. Carter Ph.D., Chairman of the Board,Independent Director
- Jay R. Luly Ph.D., President, Chief Executive Officer, Director
- Paul J. Mellett Jr., Chief Financial Officer, Senior Vice President - Finance & Administration
- Yat Sun Sun Or Ph.D., Senior Vice President - Research & Development, Chief Scientific Officer
- Nathaniel S. Gardiner J.D., Senior Vice President, General Counsel
- Nathalie Adda M.D., Senior Vice President and Chief Medical Officer
- Timothy D. Ocain Ph.D., Senior Vice President - New Product Strategy and Development
- Ernst-Gunter Afting M.D., Ph.D.,, Independent Director
- Stephen Buckley Jr., Independent Director
- George S. Golumbeski Ph.D., Independent Director
Who owns Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Krensavage Asset Management LLC (5.79%), First Manhattan Co. (4.90%), Vanguard Group Inc. (4.44%), State Street Corp (3.60%), Renaissance Technologies LLC (3.25%) and Dimensional Fund Advisors LP (2.91%). Company insiders that own Enanta Pharmaceuticals stock include Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, State Street Corp, Candriam Luxembourg S.C.A., Prudential Financial Inc., Gotham Asset Management LLC, Dupont Capital Management Corp, FMR LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Enanta Pharmaceuticals.
Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Dimensional Fund Advisors LP, ING Groep NV, First Manhattan Co., Vanguard Group Inc., Renaissance Technologies LLC, JPMorgan Chase & Co. and Goldman Sachs Group Inc.. Company insiders that have bought Enanta Pharmaceuticals stock in the last two years include Nathaniel S Gardiner and Terry Vance. View Insider Buying and Selling for Enanta Pharmaceuticals.
How do I buy Enanta Pharmaceuticals stock?
Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $43.50.
MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $38.00 (12.64% downside) |
Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Outperform -> Outperform | | High |  |
| 8/9/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $32.00 -> $38.00 | Low | |
| 8/8/2017 | Robert W. Baird | Boost Price Target | Neutral | $27.00 -> $36.00 | Medium | |
| 7/11/2017 | JMP Securities | Upgrade | Market Perform -> Outperform | $40.00 | High | |
| 2/9/2016 | Barclays PLC | Boost Price Target | Underweight | $16.00 -> $18.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)Earnings History by Quarter for Enanta Pharmaceuticals (NASDAQ ENTA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/20/2017 | | $1.88 | | | | | N/A | |
| 8/7/2017 | Q3 2017 | ($0.49) | ($0.44) | $8.08 million | $7.51 million | View | Listen | |
| 5/8/2017 | Q2 2017 | ($0.38) | ($0.28) | $9.19 million | $9.00 million | View | Listen | |
| 2/8/2017 | Q117 | ($0.18) | ($0.26) | $12.70 million | $11.90 million | View | Listen | |
| 11/21/2016 | Q416 | ($0.11) | ($0.09) | $13.56 million | $12.80 million | View | Listen | |
| 8/8/2016 | Q216 | ($0.09) | ($0.06) | $13.07 million | $14.00 million | View | Listen | |
| 5/9/2016 | Q2 | $0.10 | ($0.09) | $16.80 million | $13.00 million | View | Listen | |
| 2/8/2016 | Q116 | $1.13 | $1.36 | $47.32 million | $48.40 million | View | Listen | |
| 11/23/2015 | Q415 | $0.15 | $0.29 | $16.44 million | $14.40 million | View | Listen | |
| 8/6/2015 | Q315 | $0.19 | $0.13 | $16.18 million | $11.60 million | View | Listen | |
| 5/7/2015 | Q215 | $1.80 | $1.49 | $63.40 million | $57.40 million | View | Listen | |
| 2/5/2015 | Q115 | $3.82 | $2.18 | $86.62 million | $77.50 million | View | N/A | |
| 11/24/2014 | Q414 | ($0.33) | ($0.27) | $3.81 million | $2.60 million | View | Listen | |
| 8/11/2014 | Q314 | $1.65 | $1.81 | $40.83 million | $42.10 million | View | N/A | |
| 5/12/2014 | Q2 | $0.69 | ($0.28) | $1.20 million | $2.20 million | View | Listen | |
| 2/13/2014 | Q114 | ($0.15) | ($0.30) | $1.41 million | $0.89 million | View | N/A | |
| 11/25/2013 | Q4 | ($0.29) | ($0.25) | $1.00 million | $1.30 million | View | Listen | |
| 8/12/2013 | Q213 | ($0.34) | ($0.23) | $0.73 million | $1.60 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)Current Year EPS Consensus Estimate: $0.97 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS
Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Enanta Pharmaceuticals (NASDAQ:ENTA)Insider Ownership Percentage: 9.28%
Institutional Ownership Percentage: 66.07%
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/4/2017 | Yat Sun Or | Insider | Sell | 13,921 | $35.09 | $488,487.89 | |
| 11/29/2016 | Yat Sun Or | Insider | Sell | 13,921 | $31.44 | $437,676.24 | |
| 5/11/2016 | Nathaniel S Gardiner | VP | Buy | 500 | $24.45 | $12,225.00 | |
| 2/12/2016 | Terry Vance | Director | Buy | 2,000 | $27.04 | $54,080.00 | |
| 11/24/2015 | Paul J. Mellett | CFO | Sell | 6,000 | $30.15 | $180,900.00 | |
| 10/15/2015 | Paul J Mellett | CFO | Sell | 7,500 | $40.10 | $300,750.00 | |
| 9/8/2015 | Paul J. Mellett | CFO | Sell | 7,500 | $39.55 | $296,625.00 | |
| 7/13/2015 | Paul J Mellett | CFO | Sell | 7,500 | $46.29 | $347,175.00 | |
| 7/13/2015 | Yat Sun Or | Insider | Sell | 3,750 | $46.29 | $173,587.50 | |
| 6/11/2015 | Paul J Mellett | CFO | Sell | 7,500 | $42.51 | $318,825.00 | |
| 6/11/2015 | Yat Sun Or | Insider | Sell | 3,750 | $42.47 | $159,262.50 | |
| 6/5/2015 | Yat Sun Or | Insider | Sell | 10,750 | $42.02 | $451,715.00 | |
| 5/19/2015 | Paul J Mellett | CFO | Sell | 24,000 | $40.13 | $963,120.00 | |
| 5/11/2015 | Yat Sun Or | Insider | Sell | 8,000 | $36.13 | $289,040.00 | |
| 3/9/2015 | Jay R Luly | CEO | Sell | 15,000 | $33.37 | $500,550.00 | |
| 2/20/2015 | Jay R Luly | CEO | Sell | 15,000 | $35.35 | $530,250.00 | |
| 2/19/2015 | Stephen Jr. Buckley | Director | Buy | 1,000 | $34.00 | $34,000.00 | |
| 2/17/2015 | Nathaniel S Gardiner | VP | Buy | 1,400 | $33.23 | $46,522.00 | |
| 1/16/2015 | Paul J Mellett | CFO | Sell | 4,500 | $49.45 | $222,525.00 | |
| 1/5/2015 | Jay R Luly | CEO | Sell | 15,000 | $50.43 | $756,450.00 | |
| 12/1/2014 | Jay R Luly | CEO | Sell | 15,000 | $45.39 | $680,850.00 | |
| 11/3/2014 | Jay R Luly | CEO | Sell | 15,000 | $42.52 | $637,800.00 | |
| 9/15/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.83 | $398,300.00 | |
| 8/14/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.13 | $391,300.00 | |
| 8/14/2014 | Stephen Jr. Buckley | Director | Buy | 1,000 | $38.95 | $38,950.00 | |
| 7/14/2014 | Paul J Mellett | CFO | Sell | 20,000 | $39.88 | $797,600.00 | |
| 5/1/2014 | Yat Sun Or | Insider | Sell | 5,000 | $36.98 | $184,900.00 | |
| 4/1/2014 | Jay Luly | CEO | Sell | 15,000 | $39.17 | $587,550.00 | |
| 4/1/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.16 | $391,600.00 | |
| 3/24/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.34 | $393,400.00 | |
| 3/4/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 439,334 | $38.82 | $17,054,945.88 | |
| 2/26/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 230,190 | $39.15 | $9,011,938.50 | |
| 2/24/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 60,477 | $39.57 | $2,393,074.89 | |
| 2/14/2014 | Jay Luly | CEO | Sell | 5,800 | $38.10 | $220,980.00 | |
| 1/2/2014 | Jay R Luly | CEO | Sell | 5,800 | $28.05 | $162,690.00 | |
| 12/6/2013 | Marc E Goldberg | Director | Sell | 6,861 | $27.93 | $191,627.73 | |
| 10/14/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 32,301 | $19.84 | $640,851.84 | |
| 10/10/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 36,207 | $21.71 | $786,053.97 | |
| 10/3/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 12,300 | $23.39 | $287,697.00 | |
| 3/26/2013 | Helmut Schuhsler | Director | Buy | 132,949 | $14.00 | $1,861,286.00 | |
| 3/26/2013 | Saints Capital Granite, L.P. | Major Shareholder | Buy | 66,474 | $14.00 | $930,636.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Enanta Pharmaceuticals (NASDAQ:ENTA)
Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
| Source: |
|
| Date | Headline |
|---|
 | Reviewing Enanta Pharmaceuticals (ENTA) and The Competition
www.americanbankingnews.com - September 25 at 2:18 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 1:16 PM |
 | ETFs with exposure to Enanta Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 6:15 PM |
| Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 6:09 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Coverage Initiated at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM |
| Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors
finance.yahoo.com - September 13 at 7:40 PM |
| Enanta Pharmaceuticals (ENTA) versus Global Blood Therapeutics (GBT) Head-To-Head Analysis
www.americanbankingnews.com - September 8 at 12:30 PM |
| Nabriva Therapeutics AG (NBRV) vs. Enanta Pharmaceuticals (ENTA) Critical Contrast
www.americanbankingnews.com - September 5 at 10:22 AM |
| Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
finance.yahoo.com - August 30 at 7:35 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 1:00 PM |
| Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
finance.yahoo.com - August 28 at 6:05 PM |
| $72.75 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (ENTA) This Quarter
www.americanbankingnews.com - August 25 at 6:00 AM |
| Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)
finance.yahoo.com - August 23 at 10:42 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Earnings of $1.94 Per Share
www.americanbankingnews.com - August 23 at 2:16 PM |
| Head-To-Head Survey: Enanta Pharmaceuticals (ENTA) versus Codexis (CDXS)
www.americanbankingnews.com - August 21 at 10:22 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - August 13 at 11:58 AM |
| J P Morgan Chase & Co Reiterates "Overweight" Rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
www.americanbankingnews.com - August 10 at 12:22 AM |
| Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - August 8 at 12:46 PM |
| Edited Transcript of ENTA earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 4:39 AM |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
finance.yahoo.com - August 7 at 6:34 PM |
| Enanta Pharmaceuticals reports 3Q loss
finance.yahoo.com - August 7 at 6:34 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Quarterly Sales of $8.12 Million
www.americanbankingnews.com - August 7 at 9:12 AM |
| Enanta Pharmaceuticals, Inc. (ENTA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 5 at 1:06 PM |
| Zacks: Analysts Expect Enanta Pharmaceuticals, Inc. (ENTA) to Announce -$0.49 Earnings Per Share
www.americanbankingnews.com - August 5 at 7:14 AM |
 | Enanta Pharma (ENTA) Sees Receiving $40M Milestone Following FDA Approval of AbbVie's MAVYRET
www.streetinsider.com - August 3 at 4:59 PM |
| Enanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks
finance.yahoo.com - August 3 at 4:59 PM |
| Featured Company News – EC Grants AbbVie's MAVIRET Marketing Authorization for Treatment of Chronic Hepatitis C
finance.yahoo.com - August 1 at 6:57 PM |
| Enanta (ENTA) Announce EC Grants AbbVie (ABBV) MAA for MAVIRet for Treatment of Chronic Hepatitis C in All Major Genotypes
www.streetinsider.com - July 29 at 5:28 PM |
 | Enanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major ...
www.businesswire.com - July 28 at 8:23 PM |
| Enanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
finance.yahoo.com - July 28 at 8:23 PM |
| Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2017
finance.yahoo.com - July 25 at 6:33 PM |
| Analysts Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Post Quarterly Sales of $8.12 Million
www.americanbankingnews.com - July 16 at 10:48 AM |
| Zacks: Brokerages Anticipate Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Will Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - July 14 at 12:40 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 12 at 12:44 AM |
| ETFs with exposure to Enanta Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 7:28 PM |
| Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 12:40 PM |
 | Novus Therapeutics Announces Change in Management
www.prnewswire.com - July 11 at 4:18 AM |
 | Enanta To Retain Momentum On The Back Of Upcoming FDA Decision
seekingalpha.com - July 11 at 4:18 AM |
| Zacks Investment Research Upgrades Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to Hold
www.americanbankingnews.com - July 3 at 7:02 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 27 at 5:50 PM |
| Enanta Pharma (ENTA) Presents New Data on EDP-938
www.streetinsider.com - June 27 at 5:17 PM |
| Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at the XIX International Symposium on Respiratory Viral Infections
finance.yahoo.com - June 26 at 9:40 AM |
| Enanta Pharma (ENTA) Announces AbbVie (ABBV) Receives CHMP Positive Opinion for MAVIRET to Treat Chronic Hepatitis C in All Major Genotypes
www.streetinsider.com - June 23 at 10:38 PM |
| Enanta Announces that AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
finance.yahoo.com - June 23 at 5:35 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - June 21 at 6:20 PM |
| Zacks: Analysts Anticipate Enanta Pharmaceuticals, Inc. (ENTA) to Post -$0.49 EPS
www.americanbankingnews.com - June 20 at 12:12 AM |
| ETFs with exposure to Enanta Pharmaceuticals, Inc. : June 13, 2017
finance.yahoo.com - June 13 at 4:44 PM |
| Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ENTA-US : June 13, 2017
finance.yahoo.com - June 13 at 12:00 PM |
| Short Interest in Enanta Pharmaceuticals Inc (ENTA) Drops By 0.6%
www.americanbankingnews.com - June 11 at 7:32 AM |
| Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q2, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 10:48 AM |
Enanta Pharmaceuticals (ENTA) Chart for Tuesday, September, 26, 2017
